Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer

ConclusionsApproximately two-thirds of patients who undergo treatment with radium-223 will experience an improvement in pain and, if it occurs, it will most likely occur within the first two cycles. Patients should be counseled about this timeline and, if pain improvement isn't achieved, palliative radiation and oral analgesic readjustment should be considered. Pain response is not associated with survival and should not be used to evaluate the effectiveness of treatment.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research